Ovid Therapeutics reported a net margin of -2,047.61% for the quarter ended Jun 2026. These financial ratios cover 38 quarters of results from Mar 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2017 | Jun2017 | Sep2017 | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||||||||||||||||||||
| EBT Margin | -1,111.00% | -107,798.33% | -24,859.09% | -20,236.36% | -16,544.00% | -10,323.85% | -10,790.14% | -7,901.35% | 5,042.01% | -8,095.95% | -12,175.00% | -7,873.08% | -74.68% | -9,210.61% | 1,345.82% | -2,047.61% | ||||||||||||||||||||||
| EBIT Margin | -1,125.47% | -115,329.27% | -26,302.75% | -22,563.64% | -18,896.00% | -11,035.78% | -12,808.45% | -11,768.24% | -12,140.24% | -7,645.09% | -14,107.89% | -9,653.85% | -80.88% | -9,487.12% | -1,712.12% | -2,141.61% | ||||||||||||||||||||||
| EBITDA Margin | -1,125.47% | -115,329.27% | -26,302.75% | -22,563.64% | -18,896.00% | -11,035.78% | -12,808.45% | -11,768.24% | -12,140.24% | -7,645.09% | -14,107.89% | -9,653.85% | -80.88% | -9,487.12% | -1,712.12% | -2,141.61% | ||||||||||||||||||||||
| Operating Margin | -1,125.47% | -115,329.27% | -26,302.75% | -22,563.64% | -18,896.00% | -11,035.78% | -12,808.45% | -11,768.24% | -12,140.24% | -7,645.09% | -14,107.89% | -9,653.85% | -80.88% | -9,487.12% | -1,712.12% | -2,141.61% | ||||||||||||||||||||||
| Net Margin | -1,114.46% | -107,798.33% | -24,859.09% | -20,236.36% | -16,544.00% | -10,323.85% | -10,790.14% | -7,901.35% | 5,042.01% | -8,095.95% | -12,175.00% | -7,873.08% | -74.68% | -9,210.61% | 1,345.82% | -2,047.61% | ||||||||||||||||||||||
| FCF Margin | -1,392.89% | -114,348.52% | -20,085.72% | -18,372.73% | -15,736.00% | -9,222.02% | -8,378.87% | -11,287.16% | -8,492.31% | -8,674.57% | -13,134.21% | -7,907.69% | -76.12% | -9,751.52% | -1,449.58% | -2,401.09% | ||||||||||||||||||||||
| Efficiency | ||||||||||||||||||||||||||||||||||||||
| Assets AverageAssets Avg. | 212.54M | 200.82M | 192.82M | 184.21M | 171.18M | 160.15M | 149.32M | 139.80M | 130.63M | 134.53M | 137.82M | 124.85M | 110.37M | 97.41M | 86.91M | 79.54M | 70.64M | 107.39M | 188.28M | 228.80M | ||||||||||||||||||
| Invested CapitalInvested Cap. | 179.75M | |||||||||||||||||||||||||||||||||||||
| Asset Utilization RatioAsset Util. | 1.01 | 1.04 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.08 | 0.09 | 0.07 | 0.04 | 0.01 | ||||||||||||||||||
| Leverage & Solvency | ||||||||||||||||||||||||||||||||||||||
| Debt Ratio | ||||||||||||||||||||||||||||||||||||||
| Valuation | ||||||||||||||||||||||||||||||||||||||
| Price to EarningsP/E | -20.07 | -8.69 | -13.73 | -10.38 | -10.83 | -11.39 | -13.62 | -18.66 | -24.12 | -14.86 | -18.46 | 6.41 | -5.98 | -7.14 | -2.15 | -5.01 | -7.61 | 12.44 | -17.79 | -33.11 | ||||||||||||||||||
| Price to SalesP/S | 152.98 | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 323.36 | 484.34 | 868.94 | 169.57 | 3.74 | 700.74 | 167.40 | 678.03 | ||||||||||||||||||||||
| Price to BookP/B | 1.16 | 1.26 | 1.34 | 1.00 | 0.91 | 0.99 | 1.50 | 2.09 | 2.68 | 2.59 | 2.76 | 0.61 | 1.10 | 0.97 | 0.37 | 0.42 | 2.07 | 0.92 | 1.52 | 2.37 | ||||||||||||||||||
| Enterprise Value | 26.74M | 38.07M | 52.51M | -0.96M | -8.20M | 2.07M | 64.15M | 135.06M | 184.34M | 121.79M | 125.63M | -22.33M | 21.08M | 12.96M | -20.95M | -14.88M | 66.89M | 50.56M | 146.78M | 379.77M | ||||||||||||||||||
| EV to EBIT | -2.29 | -1.44 | -3.23 | 0.07 | 0.64 | -0.17 | -4.31 | -9.53 | -15.32 | -6.70 | -7.21 | 1.09 | -1.59 | -1.21 | 1.67 | 2.93 | -5.34 | -4.11 | -8.22 | -24.19 | ||||||||||||||||||
| EV to EBITDA | -2.29 | -1.44 | -3.23 | 0.07 | 0.64 | -0.17 | -4.31 | -9.53 | -15.32 | -6.70 | -7.21 | 1.09 | -1.59 | -1.21 | 1.67 | 2.93 | -5.34 | -4.11 | -8.22 | -24.19 | ||||||||||||||||||
| Market Capitalization | 228.54M | 225.87M | 221.11M | 151.40M | 129.66M | 131.07M | 181.87M | 231.58M | 271.41M | 227.63M | 215.89M | 54.65M | 83.79M | 66.04M | 22.04M | 23.47M | 92.50M | 120.19M | 302.30M | 496.99M | ||||||||||||||||||
| Price to FCFP/FCF | -21.00 | -18.57 | -10.98 | -10.57 | -10.21 | -14.10 | -15.00 | -19.62 | -27.00 | -19.13 | -12.92 | -3.81 | -5.58 | -6.62 | -2.14 | -4.92 | -7.19 | -11.55 | -21.75 | -28.24 | ||||||||||||||||||
| EV to FCF | -2.46 | -3.13 | -2.61 | 0.07 | 0.65 | -0.22 | -5.29 | -11.44 | -18.34 | -10.24 | -7.52 | 1.56 | -1.40 | -1.30 | 2.04 | 3.12 | -5.20 | -4.86 | -10.56 | -21.58 | ||||||||||||||||||
| EV to CFO | -2.46 | -3.17 | -2.61 | 0.07 | 0.65 | -0.23 | -5.30 | -11.54 | -18.34 | -10.23 | -7.53 | 1.57 | -1.40 | -1.30 | 2.04 | 3.12 | -5.20 | -4.86 | -10.56 | -21.58 | ||||||||||||||||||
| Return Ratios | ||||||||||||||||||||||||||||||||||||||
| Return on Sales [ROS]ROS | 60.24% | 59.61% | -1,125.47% | -4,746.67% | -115,329.27% | -26,302.75% | -22,563.64% | -18,896.00% | -11,035.78% | -12,808.45% | -11,768.24% | -12,140.24% | -7,645.09% | -14,107.89% | -9,653.85% | -80.88% | -9,487.12% | -1,712.12% | -670.25% | -2,141.61% | ||||||||||||||||||
| Return on Capital Employed [ROCE]ROCE | 63.70% | 66.77% | -36.27% | -37.99% | -41.68% | -43.67% | -48.17% | -47.94% | -61.54% | -70.23% | -71.22% | -73.47% | -58.87% | -64.01% | -42.82% | -27.67% | -26.67% | |||||||||||||||||||||
| Return on Assets [ROA]ROA | 59.66% | 61.17% | -35.93% | -36.96% | -40.11% | -33.82% | -34.43% | -35.22% | -37.14% | -38.91% | -36.77% | -23.83% | -29.45% | -27.13% | -28.73% | -48.00% | -51.43% | -16.22% | -12.84% | -15.08% |